Found: 25
Select item for more details and to access through your institution.
Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in Japan.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 702, doi. 10.1007/s10637-018-0603-z
- By:
- Publication type:
- Article
A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 674, doi. 10.1007/s10637-018-0599-4
- By:
- Publication type:
- Article
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 732, doi. 10.1007/s10637-018-0598-5
- By:
- Publication type:
- Article
Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 715, doi. 10.1007/s10637-018-0586-9
- By:
- Publication type:
- Article
Autophagy inhibition improves the chemotherapeutic efficacy of cruciferous vegetable-derived diindolymethane in a murine prostate cancer xenograft model.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 718, doi. 10.1007/s10637-018-0595-8
- By:
- Publication type:
- Article
A phase I/II trial of pemetrexed plus radiotherapy in elderly patients with locally advanced non-small cell lung cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 667, doi. 10.1007/s10637-018-0587-8
- By:
- Publication type:
- Article
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 657, doi. 10.1007/s10637-018-0585-x
- By:
- Publication type:
- Article
Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 726, doi. 10.1007/s10637-018-0596-7
- By:
- Publication type:
- Article
The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 581, doi. 10.1007/s10637-017-0556-7
- By:
- Publication type:
- Article
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 683, doi. 10.1007/s10637-018-0580-2
- By:
- Publication type:
- Article
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 709, doi. 10.1007/s10637-018-0579-8
- By:
- Publication type:
- Article
Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 590, doi. 10.1007/s10637-017-0557-6
- By:
- Publication type:
- Article
Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 696, doi. 10.1007/s10637-018-0581-1
- By:
- Publication type:
- Article
A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 647, doi. 10.1007/s10637-017-0544-y
- By:
- Publication type:
- Article
Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cells.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 523, doi. 10.1007/s10637-017-0543-z
- By:
- Publication type:
- Article
Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (CAFs) by synergistic induction of apoptosis.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 545, doi. 10.1007/s10637-017-0547-8
- By:
- Publication type:
- Article
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 536, doi. 10.1007/s10637-017-0545-x
- By:
- Publication type:
- Article
Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 571, doi. 10.1007/s10637-017-0552-y
- By:
- Publication type:
- Article
Development of a dietary formulation of the SHetA2 chemoprevention drug for mice.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 561, doi. 10.1007/s10637-017-0550-0
- By:
- Publication type:
- Article
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 638, doi. 10.1007/s10637-017-0534-0
- By:
- Publication type:
- Article
Radiomics to predict immunotherapy-induced pneumonitis: proof of concept.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 601, doi. 10.1007/s10637-017-0524-2
- By:
- Publication type:
- Article
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 619, doi. 10.1007/s10637-017-0531-3
- By:
- Publication type:
- Article
Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 608, doi. 10.1007/s10637-017-0527-z
- By:
- Publication type:
- Article
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 629, doi. 10.1007/s10637-017-0532-2
- By:
- Publication type:
- Article
Combined treatment with pemetrexed and vinflunine in patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy - results of an exploratory phase I study.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 615, doi. 10.1007/s10637-017-0528-y
- By:
- Publication type:
- Article